Saturday 17 October 2026
Export TXMD’s income statement to Excel — free account
TherapeuticsMD, Inc.
TXMD Healthcare Drug Manufacturers Specialty & Generic
TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024. In the quarter to June 2026, revenue fell 8.72%, EPS fell 80.0% and free cash flow grew 104.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.90
0.03
−1.55%
Follow TXMD
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 6 | 3 | 7 | 2 | 2 | 4 | 1 | 5 | 5 |
Altman Z-Score |
(34.36) | (34.06) | (30.18) | (13.06) | (10.84) | (8.13) | (3.26) | (0.06) | 51.52 | 41.36 |
P/S ratio |
6.24 | 5.63 | 18.68 | 0.81 | 55.69 | 5.14 | 12.01 | 53.25 | 76.81 | 60.48 |
P/FCF ratio |
9.07 | 12.49 | 0.00 | 6.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(78.93) | (77.28) | (69.86) | (32.48) | (28.92) | (19.46) | (8.47) | (6.71) | 3.58 | 3.32 |
P/Operating CF |
50.29 | 583.38 | (4.90) | 1.87 | 2.98 | (10.99) | (11.73) | (30.46) | (61.94) | (74.96) |
Beneish M-Score |
(2.54) | (2.58) | — | — | 19.79 | (2.86) | (0.87) | (1.67) | (2.51) | (2.96) |
P/B ratio |
0.70 | 0.36 | 0.83 | 1.61 | 0.00 | 0.00 | 64.79 | 8.79 | 9.92 | 9.18 |
Price to Tangible BV |
0.82 | 0.43 | 1.05 | 2.00 | 0.00 | 0.00 | 0.00 | 11.68 | 10.16 | 9.36 |
EV/Sales |
91.57 | 153.43 | 219.16 | 3.89 | 170.38 | 7.60 | 12.72 | 47.77 | 69.23 | 53.68 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 114.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
112.76 | 230.94 | (12.36) | 29.11 | (7.95) | (3.09) | (3.81) | (7.20) | (15.25) | (15.03) |
EV/FCF |
133.16 | 340.30 | (12.16) | 30.33 | (7.64) | (3.06) | (3.33) | (6.00) | (15.09) | (14.76) |
Quick Ratio |
2.30 | 1.67 | 1.08 | 1.05 | 0.40 | 1.91 | 3.49 | 4.20 | 9.87 | 9.08 |
Current Ratio |
3.02 | 2.37 | 1.72 | 1.18 | 0.47 | 2.17 | 3.93 | 4.55 | 10.48 | 9.30 |
Net Debt/EBITDA |
2.34 | 1.05 | 0.57 | (20.69) | (1.56) | (1.05) | (0.24) | 0.68 | 1.64 | 1.46 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 111.09% | 132.12% | 73.74% | 34.62% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | (2.01) | (1.94) | 21.32 | 0.75 | 0.00 | 0.00 |
Asset Turnover |
0.08 | 0.04 | 0.02 | 0.54 | 0.01 | 0.29 | 0.21 | 0.09 | 0.12 | 0.18 |
Operating CF/Net income |
(4.31) | (0.54) | 2.25 | 0.08 | 0.32 | 0.87 | 0.94 | 0.81 | 0.99 | 0.77 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.30) | (3.02) | (0.39) | (17.16) | (37.83) | (3.88) | (9.37) |
Interest Coverage |
— | — | — | — | (2.42) | (5.44) | (8.70) | (27.84) | (10,081.65) | (8,356.81) |
| (2.10%) | (7.70%) | (31.90%) | (383.04%) | 158.45% | 319.73% | (330.09%) | (116.62%) | (59.77%) | (94.33%) | |
| (1.49%) | (5.31%) | (15.37%) | 86.17% | (98.22%) | (82.00%) | (73.71%) | (74.67%) | (53.85%) | (83.14%) | |
ROIC |
(14.15%) | (17.12%) | (21.34%) | 0.00% | (167.23%) | (274.11%) | (212.33%) | (875.89%) | (1,749.59%) | 0.00% |
Return on Tangible Assets |
(5.89%) | (30.75%) | (207.97%) | 1,303.81% | 130.03% | (258.09%) | (111.54%) | (90.73%) | (60.73%) | (71.93%) |
Average Days of Receivables |
425.75 | 738.29 | 866.24 | 0.00 | 5,131.85 | 182.20 | 179.36 | 250.83 | 94.17 | 84.87 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.08% | 39.87% | 169.56% | 201.77% | 278.68% |
Selling, General and Administrative Expense of Revenue |
226.74% | 346.17% | 683.79% | 81.06% | 3,138.28% | 299.06% | 351.93% | 720.45% | 343.93% | 265.28% |
Intangible Assets out of Total Assets |
0.10 | 0.11 | 0.14 | 0.08 | 0.04 | 0.23 | 0.17 | 0.11 | 0.02 | 0.02 |
Share Based Compensation of Revenue |
2.48% | 14.99% | 97.62% | 16.54% | 704.43% | 16.46% | 21.52% | 53.80% | 41.06% | 89.95% |
Graham Net Nets |
0.19 | 0.08 | (0.09) | 0.00 | (1.00) | (0.53) | (0.08) | 0.08 | 0.10 | 0.11 |
Graham Number |
0.00 | 0.00 | 0.00 | 32.96 | 75.43 | 130.21 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(3.28%) | (20.71%) | (42.62%) | 198.43% | (119.44%) | (55.37%) | (29.34%) | (15.49%) | (6.06%) | (7.87%) |
Free Cash Flow Yield |
11.02% | 8.01% | (96.42%) | 15.92% | (40.03%) | (48.29%) | (31.80%) | (14.95%) | (5.97%) | (6.01%) |
Revenue per Share |
0.26 | 0.15 | 0.12 | 7.75 | 0.32 | 11.77 | 10.08 | 3.58 | 4.08 | 4.94 |
Operating CF per Share |
0.21 | 0.10 | (2.21) | 1.04 | (6.93) | (28.93) | (33.63) | (23.73) | (18.53) | (17.63) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.04) | (0.28) | (0.29) | (4.85) | (4.74) | (0.20) | (0.32) |
Free Cash Flow per Share |
0.21 | 0.10 | (2.21) | 1.00 | (7.21) | (29.22) | (38.48) | (28.47) | (18.73) | (17.95) |
Cash per Share |
0.65 | 0.44 | 0.41 | 5.46 | 8.15 | 14.60 | 32.64 | 35.91 | 30.93 | 33.54 |
Shareholders Equity per Share |
2.32 | 2.37 | 2.81 | 3.89 | (11.76) | (22.49) | 1.87 | 21.67 | 31.60 | 32.51 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.32 | 2.37 | 2.81 | 3.89 | (11.76) | (22.49) | 1.87 | 21.67 | 31.60 | 32.51 |
Free Cash Flow |
2.45 | 1.17 | (23.08) | 9.00 | (57.36) | (161.07) | (189.61) | (128.13) | (76.98) | (70.38) |
Working Capital |
9.66 | 7.09 | 4.94 | 8.51 | (133.42) | 69.17 | 155.41 | 145.70 | 126.23 | 124.43 |
Capital Expenditures |
— | — | — | (0.35) | (2.22) | (1.60) | (23.89) | (21.32) | (0.83) | (1.24) |
Net Current Asset Value |
3.67 | 0.81 | (2.23) | 0.04 | (143.62) | (177.21) | (48.37) | 72.32 | 126.23 | 124.43 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 228.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | 0.86 | 0.02 | 0.48 | 1.32 | 0.05 | 0.06 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 47.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 15.29 | 0.89 | 2.09 | 0.56 | 1.19 | 0.49 | 0.26 |
Cash ROIC |
7.14% | 3.61% | (68.66%) | 10.66% | (35.95%) | (82.00%) | (51.78%) | (38.53%) | (29.95%) | (27.17%) |
Accounts Receivable Turnover |
0.85 | 0.53 | 0.07 | 0.00 | 0.08 | 2.29 | 2.80 | 2.09 | 3.80 | 5.13 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.50 | 0.11 | 0.79 | 0.30 | 0.20 | 0.46 | 0.80 |
Inventory Turnover |
— | — | — | 0.00 | 0.18 | 1.61 | 0.84 | 1.15 | 2.06 | 4.74 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 564.87 | 878.13 | 481.37 | 1,105.15 | 3,032.29 | 567.19 | 641.67 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 182.63 | 683.37 | 435.66 | 205.61 | 93.86 |
Average Receivables |
3.54 | 3.33 | 19.63 | — | 34.28 | 28.39 | 17.73 | 7.70 | 4.41 | 3.78 |
Average Payables |
0.32 | 0.14 | 1.09 | 2.77 | 12.22 | 20.12 | 20.96 | 13.42 | 5.73 | 5.24 |
Average Inventory |
— | — | — | — | 7.81 | 9.93 | 7.56 | 2.38 | 1.28 | 0.88 |
Average Assets |
38.24 | 41.07 | 66.88 | 129.97 | 175.54 | 223.80 | 238.98 | 177.61 | 142.85 | 108.10 |
Average Common Equity |
27.12 | 28.33 | 32.22 | (29.24) | (108.81) | (57.40) | 53.36 | 113.72 | 128.70 | 95.28 |
Columns are period end dates